{
  "docId": "019de074-461e-7658-adac-5d98e29da216",
  "docSlug": "6158bdf12351a4a226761fe3aa786b96",
  "documentTitle": "Alkermes | Results Presentation Deck | 24 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 24,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_takeaways",
  "function": "prioritize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-461e-7658-adac-5d98e29da216/19",
  "deckHref": "/decks/019de074-461e-7658-adac-5d98e29da216",
  "deckJsonHref": "/decks/019de074-461e-7658-adac-5d98e29da216.json",
  "deckAnchorHref": "/decks/019de074-461e-7658-adac-5d98e29da216#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "1. Drive launch of LYBALVI. Continued execution of commercial strategy and investment in DTC campaign. 2. Advance orexin 2 receptor agonist. Establish initial safety and tolerability profile and generate initial clinical proof-of-concept data for ALKS 2680. 3. Separate oncology business. Clarify value proposition for standalone neuroscience and oncology businesses.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5945920-0941-4a97-a786-01c3d59e71b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "subtitle",
      "text": "DTC: Direct-to-consumer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31eafe4c-d2dc-4b90-95ff-8670ef7add00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Clear Priorities to Unlock Value in 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29468f99-11d8-4400-a9a2-e992f5e4c416",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "title",
      "text": "2023 Business Priorities and Value Drivers",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d5b2c2b-51ae-4747-8596-450c366da264",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "3faf0748-899e-4a45-a68c-70bac4dae82c",
      "evidence": "The slide uses a numbered list to present three distinct strategic priorities.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 19,
      "from": 15,
      "beatId": "d30c4575-f1a8-4345-8643-089f1c290b77",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "2023 Outlook and Planned Separation",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 15-19 provide an update on the company's 2023 outlook and planned separation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 19,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "173eb554-351f-4bf0-a453-021007485622",
      "evidence": "Slide 19 emphasizes the company's priorities to unlock value in 2023",
      "position": 0,
      "objective": "Highlighting the importance of unlocking value in 2023",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}